Pfizer (NYSE:PFE) expects common stock for its Viatris spin-off to be available starting Nov. 12, following the U.S. Federal Trade Commission’s approval of the proposed merger of Mylan (NSDQ:MYL) and Pfizer’s biopharmaceutical Upjohn brand. The company expects the “when-issued” market for Viatris common stock (VTRSV) to be available from Nov. 12 to Nov. 16, when it…
FTC blesses merger of Mylan and Pfizer’s Upjohn division
Mylan (NSDQ:MYL) and Pfizer (NYSE:PFE) recently announced that the U.S. Federal Trade Commission had signed off on the proposed merger of Mylan and Pfizer’s biopharmaceutical-focused Upjohn brand. Upjohn also includes Pfizer’s Greenstone generic-drug unit. It also owns the rights to Lipitor and Xanax. Pfizer plans to spin out Upjohn on Nov. 13. If all goes…